Yes , I think you are right , during this time he
Post# of 148319
IMO not that many unknowns in HIV right now for this price , this is only USA ,
Soon we be doing study for PrEP in Asia , we expecting study to be very positive ,
They planning to apply in Europe as soon combo approved here. Europe is twice as big.
About 37-38 mill HIV patients globally so about 26,000,000 mill CCR5 positive..
2017 we had 2,000,000 mill new HIV patients globally ,
HIV is still extremely serious problem , more and more resistance, and side effects.
I think week ago Thursday Merck had R& D day.
When they talked about HIV , they said 2 mill new patients globally with HIV in 2017 , many different drugs available now ,
New drug to be successful must:
- account for missed doses,
- account for patients pill fatigue,
- be easy and effective option for PrEP.
- decrease toxicity and resistance
I know medicine like that !!!!!!!, again that was on Merck meeting 6 days ago.
About cancers they talked about different pathways they learning to attack cancers ,
very first they put it was threw CCR5...
,